Clinical trial
Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT04681118 is registered in ClinicalTrials.gov with Brainstorm-Cell Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Brainstorm-Cell Therapeutics
- Phase
- Expanded access
- Overall status
- No longer available
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.